logo
  

Novartis : Late-stage Study On Cosentyx Meets Primary Endpoint In Juvenile Idiopathic Arthritis

Novartis (NVS) said that phase III JUNIPERA study met its primary endpoint, with Cosentyx or secukinumab showing significantly longer time to flare (longer time to worsening of symptoms) compared to placebo in pediatric patients with two subtypes of juvenile idiopathic arthritis or JIA.

Cosentyx demonstrated a favorable safety profile with no new safety signals reported in pediatric patients (age 2 to 17 years) with two years of treatment.

The subtypes juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA) are progressive, debilitating diseases associated with high levels of pain and functional disability, affecting children as young as two years old.

Both juvenile psoriatic arthritis and enthesitis-related arthritis are progressive, chronic, debilitating diseases with limited treatment options. Juvenile idiopathic arthritis can impact the daily lives of children and teenagers, with over 30% of children with Juvenile idiopathic arthritis finding it difficult to attend school due to their condition, and many children still having active disease as adults.

Cosentyx is human biologic that directly inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation and development of psoriatic arthritis (PsA), psoriasis and axial spondyloarthritis (axSpA).

Regulatory submissions in Europe and the US are anticipated in the coming weeks. In August 2020, Cosentyx received EU approval as a first-line systemic treatment for pediatric psoriasis and recently received US approval for the same indication.

Cosentyx has approvals across four indications, and is supported by long-term five-year sustained efficacy and safety data across psoriasis, psoriatic arthritis and ankylosing spondylitis, with more than 400,000 patients treated worldwide since launch.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sturtevant, Wisconsin-based BRP U.S. Inc. is recalling around 20 models of Side-by-Side vehicles citing fire risk, the U.S. Consumer Product Safety Commission. The recall involves about 34,400 units of Model Years 2020 and 2021 Can-AM Defender HD10 side-by-side vehicles. While reporting financial results for the second quarter on Friday, technology company Honeywell international Inc. (HON) raised its adjusted earnings and sales guidance for the full-year 2021, based on the second-quarter performance and management's outlook for the remainder of the year. For fiscal... Shares of Vodafone Group Plc were gaining around 2 percent in the morning trading in London after the British telecom major reported higher revenues in its first quarter. Looking ahead, the company said it is on track to deliver fiscal year 2022 guidance, with Adjusted EBITDAaL expected to be between 15.0 billion euros - 15.4 billion euros and Adjusted free cash flow of at least 5.2 billion euros
Follow RTT